There are currently 1336 clinical trials in Columbus, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Nationwide Children's Hospital, Ohio State University Comprehensive Cancer Center, Ohio State University and The Ohio State University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Gene Hunting Study for Familial Papillary Thyroid Cancer
NCT02776969
Recruiting
The aim of this project is to identify genetic risk factors associated with familial papillary thyroid carcinoma (PTC). Papillary thyroid cancer is a type of cancer that shows high heritability. However, the specific genetic factors that cause an increased risk have been elusive.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/13/2022
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Thyroid
Register for Updates
Study of TL-895 in Subjects With Myelofibrosis
NCT04655118
Recruiting
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/11/2022
Locations: Ohio State University, Columbus, Ohio
Conditions: Myelofibrosis
Register for Updates
Ketogenic Diet in Patients With Heart Failure
NCT04235699
Recruiting
This study is being done to evaluate the effects of a low carbohydrate ketogenic diet on exercise tolerance in patients with Heart Failure with Preserved Ejection Fraction (HFpEF), also known as Diastolic Heart Failure (DHF).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
10/10/2022
Locations: The Ohio State University, Columbus, Ohio
Conditions: Heart Failure With Preserved Ejection Fraction
Register for Updates
Research and Innovation to Stop E-cigarette/Vaping in Young Adults
NCT04974580
Recruiting
The aim of this study is to test intervention components to help young adults quit vaping. A 2x2 factorial design will be used where all participants receive quitline-delivered behavioral phone counseling, and components to be tested are a digital intervention (with text and online cessation support) and nicotine replacement therapy (NRT). The research questions and hypotheses for this study are: Which components and combinations of intervention yield the greatest success rates for exclusive v... Read More
Gender:
All
Ages:
Between 18 years and 24 years
Trial Updated:
10/03/2022
Locations: The Ohio State University, Columbus, Ohio
Conditions: Nicotine Dependence, E-Cig Use
Register for Updates
Continuous Glucose Monitoring for Various Degrees of Glucose Intolerance
NCT05491954
Recruiting
Diabetes mellitus affects roughly 8% of pregnancies but is associated with significant perinatal and maternal morbidity, with 6% of pregnancies affected by gestational diabetes mellitus (GDM). Best practice guidelines recommend universal screening for gestational diabetes mellitus between 24-28 weeks of pregnancy in all women who do not have a diagnosis of pre-gestational diabetes mellitus. Among high-risk populations, performing an early diabetes screen is suggested at the initiation of prenata... Read More
Gender:
Female
Ages:
Between 18 years and 45 years
Trial Updated:
09/19/2022
Locations: The Ohio State University Medical Center, Columbus, Ohio
Conditions: Diabetes, Gestational
Register for Updates
Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement
NCT03716531
Recruiting
This research study is studying an intervention as a possible treatment for pancreatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Pancreas Cancer
Register for Updates
Genetic and Cognitive Predictors of Aphasia Treatment Response
NCT05179538
Recruiting
Aphasia, or language impairment after a stroke, affects approximately 2 million people in the United States, with an estimated 180,000 new cases each year. The medical community cannot predict how well someone with aphasia will respond to treatment, as some people with aphasia are poor responders to intervention even when participating in empirically supported treatments. There is a strong likelihood that genetics play a role in language recovery after stroke, but very little research has been d... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
09/02/2022
Locations: The Ohio State University, Columbus, Ohio
Conditions: Aphasia
Register for Updates
Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children
NCT04492683
Recruiting
Study to assess the diagnostic accuracy (sensitivity, specificity, positive and negative predictive value) of DBV1605 for the diagnosis of non-Immunoglobulin E (IgE) mediated cow's milk allergy (CMA) in children with symptoms suggestive of non-IgE mediated CMA.
Gender:
All
Ages:
Between 29 days and 24 months
Trial Updated:
08/09/2022
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Cow's Milk Allergy
Register for Updates
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)
Gender:
All
Ages:
18 years and above
Trial Updated:
08/03/2022
Locations: The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Register for Updates
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months
NCT04909021
Recruiting
This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as a nasal spray. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 6 and 24 months who are seronegative to RSV.
Gender:
All
Ages:
Between 6 months and 36 months
Trial Updated:
08/01/2022
Locations: Aventiv Research, Columbus, Ohio
Conditions: Respiratory Syncytial Virus (RSV)
Register for Updates
Continuous Glucose Monitoring for Personal Protective Equipment Evaluation
NCT05478070
Recruiting
Diabetes mellitus (DM) affects roughly 8% of pregnancies and is associated with significant perinatal and maternal morbidity. Current obstetric practice is complicated by the emergence of the SARS-COV-2 pandemic, resulting in morbidity and mortality secondary to complications of COVID-19. Care coordination among the teams caring for women admitted for antepartum, intrapartum, and postpartum care with suspected or confirmed COVID-19 is required to conserve PPE and minimize staff exposure. The inv... Read More
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
07/26/2022
Locations: The Ohio State University Medical Center, Columbus, Ohio
Conditions: Diabetes Mellitus (DM)
Register for Updates
Evaluating E-Cigarette Nicotine Form, Concentration, and Flavors Among Youth
NCT05458895
Recruiting
This clinical trial examines the influence of nicotine form, concentration, and e-liquid flavor on youth vaping behavior, as well as the heart and lung effects associated with this behavior. Electronic cigarette (e-cig) "vaping", while being promoted as a safer alternative to conventional cigarettes, has disproportionately attracted adolescents and young adults ("youth"). This trial may help researchers understand how nicotine form, concentration, and flavor affects people's vaping behaviors and... Read More
Gender:
All
Ages:
Between 21 years and 25 years
Trial Updated:
07/13/2022
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: E-cigarette Use
Register for Updates